| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Llorens Revull, Meritxell |
| dc.contributor.author | Dopazo Taboada, Cristina |
| dc.contributor.author | Rodríguez Frias, Francisco |
| dc.contributor.author | Garcia Cehic, Damir |
| dc.contributor.author | Soria Benito, Maria Eugenia |
| dc.contributor.author | Chen, Qian |
| dc.contributor.author | Perales Viejo, Celia Belen |
| dc.contributor.author | Quer Sivila, Josep |
| dc.contributor.author | Bilbao Aguirre, Itxarone Izaskun |
| dc.contributor.author | Rando Segura, Ariadna |
| dc.contributor.author | Gregori Font, Josep |
| dc.contributor.author | Esteban Mur, Juan Ignacio |
| dc.date.accessioned | 2022-05-30T11:26:20Z |
| dc.date.available | 2022-05-30T11:26:20Z |
| dc.date.issued | 2021-11 |
| dc.identifier.citation | Llorens-Revull M, Gregori J, Dopazo C, Rodriguez-Frías F, Garcia-Cehic D, Soria ME, et al. Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients. Genes. 2021 Nov;12(11):1731. |
| dc.identifier.issn | 2073-4425 |
| dc.identifier.uri | https://hdl.handle.net/11351/7578 |
| dc.description | Fibrosis; Hepatitis C virus; Viral load |
| dc.description.abstract | Cirrhosis derived from chronic hepatitis C virus (HCV) infection is still a common indication for liver transplantation (LT). Reinfection of the engrafted liver is universal in patients with detectable viral RNA at the time of transplant and causes fast progression of cirrhosis (within 5 years) in around one-third of these patients. To prevent damage to the liver graft, effective direct-acting antiviral (DAA) therapy is required as soon as possible. However, because of post-LT clinical instability, it is difficult to determine the optimal time to start DAAs with a low risk of complications. Evaluate changes in quasispecies complexity following LT and seek a predictive index of fast liver damage progression to determine the timing of DAA initiation. HCV genomes isolated from pre-LT and 15-day post-LT serum samples of ten patients, who underwent orthotopic LT, were quantified and sequenced using a next-generation sequencing platform. Sequence alignments, phylogenetic trees, quasispecies complexity measures, biostatistics analyses, adjusted R2 values, and analysis of variance (ANOVA) were carried out. Three different patterns of reinfection were observed (viral bottlenecking, conserved pre-LT population, and mixed populations), suggesting that bottlenecking or homogenization of the viral population is not a generalized effect after liver graft reinfection. None of the quasispecies complexity measures predicted the future degree of liver damage. Higher and more uniform viral load (VL) values were observed in all pre-LT samples, but values were more dispersed in post-LT samples. However, VL increased significantly from the pre-LT to 15-day post-LT samples in patients with advanced fibrosis at 1-year post-LT, suggesting that a VL increase on day 15 may be a predictor of fast liver fibrosis progression. HCV kinetics after LT differ between patients and are not fibrosis-dependent. Higher VL at day 15 post-LT versus pre-LT samples may predict fast liver fibrosis progression. |
| dc.language.iso | eng |
| dc.publisher | MDPI |
| dc.relation.ispartofseries | Genes;12(11) |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Virus de l'hepatitis C |
| dc.subject | Fetge - Trasplantació - Complicacions |
| dc.subject | Fetge - Malalties - Prognosi |
| dc.subject.mesh | Hepatitis C, Chronic |
| dc.subject.mesh | Liver Transplantation |
| dc.subject.mesh | Disease Progression |
| dc.title | Study of Quasispecies Complexity and Liver Damage Progression after Liver Transplantation in Hepatitis C Virus Infected Patients |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.3390/genes12111731 |
| dc.subject.decs | hepatitis C crónica |
| dc.subject.decs | trasplante de hígado |
| dc.subject.decs | progresión de la enfermedad |
| dc.relation.publishversion | https://doi.org/10.3390/genes12111731 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Llorens-Revull M, Quer J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Gregori J] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain. Roche Diagnostics SL, 08174 Sant Cugat del Vallès, Spain. [Dopazo C] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain. Unitat de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Rodriguez-Frías F] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain. Departament de Bioquímica i Biologia Molecular, Universitat Autònoma de Barcelona, Bellaterra, Spain. Servei de Bioquímica i Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Garcia-Cehic D, Perales C] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain. [Soria ME, Chen Q] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Rando A] Servei de Bioquímica i Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Esteban JI] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat del Fetge, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Bilbao I] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain. Unitat de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Departament de Cirurgia, Universitat Autònoma de Barcelona, Bellaterra, Spain |
| dc.identifier.pmid | 34828337 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00533 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00301 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CP14%2F00121 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |